Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Narcotic Antagonists | 9 | 2019 | 165 | 2.180 |
Why?
|
| Naltrexone | 8 | 2019 | 139 | 2.170 |
Why?
|
| Analgesics, Opioid | 9 | 2019 | 472 | 1.710 |
Why?
|
| Constipation | 2 | 2019 | 69 | 1.080 |
Why?
|
| Receptors, Opioid, mu | 7 | 2016 | 45 | 0.710 |
Why?
|
| Quaternary Ammonium Compounds | 8 | 2019 | 81 | 0.620 |
Why?
|
| Morphine | 3 | 2014 | 130 | 0.530 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2014 | 16 | 0.460 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 275 | 0.380 |
Why?
|
| Ileus | 1 | 2010 | 11 | 0.330 |
Why?
|
| Anesthesia, General | 1 | 2010 | 119 | 0.320 |
Why?
|
| Gastric Emptying | 1 | 2008 | 25 | 0.310 |
Why?
|
| Drug Design | 1 | 2008 | 130 | 0.290 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 145 | 0.280 |
Why?
|
| Burns | 1 | 2008 | 145 | 0.260 |
Why?
|
| Gastrointestinal Tract | 1 | 2008 | 192 | 0.260 |
Why?
|
| Fluorouracil | 1 | 2008 | 549 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 410 | 0.260 |
Why?
|
| Neoplasms | 3 | 2016 | 3117 | 0.250 |
Why?
|
| Gastrointestinal Transit | 1 | 2005 | 19 | 0.240 |
Why?
|
| Plant Preparations | 1 | 2004 | 21 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1398 | 0.220 |
Why?
|
| Warfarin | 1 | 2004 | 105 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2004 | 136 | 0.210 |
Why?
|
| Panax | 1 | 2004 | 170 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1399 | 0.190 |
Why?
|
| Anticoagulants | 1 | 2004 | 443 | 0.180 |
Why?
|
| Disease Progression | 4 | 2014 | 1503 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2014 | 1138 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1771 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2458 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 364 | 0.150 |
Why?
|
| Male | 10 | 2019 | 43925 | 0.150 |
Why?
|
| Cell Movement | 2 | 2014 | 797 | 0.140 |
Why?
|
| Humans | 17 | 2019 | 92337 | 0.140 |
Why?
|
| Female | 9 | 2019 | 47893 | 0.140 |
Why?
|
| Laxatives | 1 | 2016 | 13 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 3053 | 0.130 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1756 | 0.130 |
Why?
|
| Adult | 6 | 2019 | 27532 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 2394 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2008 | 475 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 866 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2005 | 337 | 0.110 |
Why?
|
| Epidermal Growth Factor | 1 | 2014 | 118 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 1181 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 101 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2019 | 8740 | 0.100 |
Why?
|
| Adhesins, Bacterial | 1 | 2012 | 36 | 0.100 |
Why?
|
| Lectins | 1 | 2012 | 86 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2012 | 101 | 0.090 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2010 | 24 | 0.090 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2008 | 86 | 0.090 |
Why?
|
| Receptors, Opioid | 1 | 2010 | 23 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 209 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 207 | 0.080 |
Why?
|
| Heroin Dependence | 1 | 2010 | 15 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 128 | 0.080 |
Why?
|
| Animals | 8 | 2015 | 28003 | 0.080 |
Why?
|
| Gastrointestinal Motility | 1 | 2008 | 25 | 0.080 |
Why?
|
| Mice | 6 | 2015 | 12110 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2010 | 2087 | 0.080 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2008 | 12 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 109 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 103 | 0.070 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2008 | 76 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 350 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2008 | 312 | 0.070 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2007 | 37 | 0.070 |
Why?
|
| Reishi | 1 | 2007 | 7 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2008 | 270 | 0.070 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 814 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 698 | 0.070 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2007 | 67 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1720 | 0.070 |
Why?
|
| Capillary Permeability | 1 | 2007 | 133 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2008 | 2902 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 298 | 0.060 |
Why?
|
| Critical Illness | 1 | 2008 | 328 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 97 | 0.060 |
Why?
|
| Middle Aged | 3 | 2016 | 27030 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 238 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 434 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 37 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2004 | 245 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 977 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2014 | 2669 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1786 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 502 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 569 | 0.040 |
Why?
|
| Aged | 1 | 2016 | 19943 | 0.040 |
Why?
|
| United States | 1 | 2008 | 7348 | 0.030 |
Why?
|
| Anesthetics | 1 | 2014 | 53 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 180 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 291 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3360 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 74 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 328 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2012 | 113 | 0.020 |
Why?
|
| Virulence | 1 | 2012 | 277 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2014 | 498 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 288 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 828 | 0.020 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2007 | 22 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.020 |
Why?
|
| Thirst | 1 | 2007 | 19 | 0.020 |
Why?
|
| Thrombin | 1 | 2007 | 60 | 0.020 |
Why?
|
| Naloxone | 1 | 2007 | 69 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 402 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2505 | 0.020 |
Why?
|
| Fatigue | 1 | 2007 | 177 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2007 | 162 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 673 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 561 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 389 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3508 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3017 | 0.010 |
Why?
|